In various embodiments of the present invention, a capsule is provided including a hydrophobic inner layer and at least one hydrophilic outer layer. The hydrophobic layer may include a hydrophilic component such as an active pharmaceutical ingredient (API) which may be fully encapsulated, partially encapsulated or part of an adsorption complex. Such capsules experience no or minimal cracking or breaking in the outer layer.
Compositions And Capsules With Stable Hydrophilic Layers
Several embodiments of the present invention provide a capsule including a hydrophobic inner core layer and at least one hydrophilic outer layer. The outer layer may be seamless and may include at least one hygroscopic polyol and at least one polyol with a low hygroscopicity. The at least one outer layer may include at least one film or gel forming agent. Such capsules are stable and experience minimal or no degradation under accelerated stability conditions.
Dongzhou Liu - Parsippany NJ, Kanji Meghpara - Parsippany NJ,
GlaxoSmithKline, LLC - Philadelphia
A61K 9/24 A61K 31/167
The present invention is directed to twice daily sustained release pharmaceutical composition of paracetamol having an immediate release phase of paracetamol and a sustained release phase of paracetamol, said composition having unique and advantageous pharmacokinetic properties and a pharmaceutical composition comprising only a sustained release phase of paracetamol having unique and advantageous pharmacokinetic properties.
Principal Scientist At Glaxosmithkline Biologicals
Principal Scientist at GlaxoSmithKline Biologicals, Principal Scientist at GlaxoSmithKline Consumer Healthcare Ltd., Principal Scientist at GSK CHRD, Principal Scientist at GSK Consumer Healthcare, Principal Scientist at GlaxoSmithKline
Greater New York City Area
GlaxoSmithKline Consumer Healthcare Ltd. since 2008
GSK CHRD since 2008
GSK Consumer Healthcare since 2008
GlaxoSmithKline since 2008